LB Pharmaceuticals has granted Christopher Zergebel, its new Senior Vice President of Clinical Operations, an inducement equity award of 75,000 stock options. The options have a ten-year term, an exercise price of $32.95 per share, and vest over four years. This grant is part of the Nasdaq Listing Rule 5635(c)(4) inducement exception to attract key talent. LB Pharmaceuticals is advancing its lead drug candidate LB-102 for neuropsychiatric disorders, with ongoing Phase 3 and Phase 2 clinical trials targeting schizophrenia and bipolar depression.
YSX Tech Co., Ltd announced a 16.8% revenue increase to $83.5 million for fiscal year 2026, driven by a 28.8% rise in service volumes, especially in vehicle risk screening services which grew 112.1%. The company shifted focus from individual insuranc...
UBS Group AG has notified Bang & Olufsen A/S that its shareholding and voting rights have dropped below the 5% threshold, holding 4.85% as of July 8, 2026. This update is in accordance with the Danish Capital Markets Act, which requires disclosure wh...
Assassin’s Creed Black Flag Resynced, a remake of the 2013 original, sold 2 million copies on its first day, marking a strong launch for Ubisoft. The game achieved the highest concurrent player count ever for the franchise on Steam and topped Twitch ...
VKNG Digital, founded by marketing expert Dave Anderson, has launched to provide high-quality SEO and PPC strategies to small and medium-sized businesses in Lancashire. The agency aims to bridge the gap where smaller businesses often lack access to e...
Frontier Nuclear and Minerals Inc. received a Nasdaq notice on July 6, 2026, for failing to file its interim financial report for the six months ending December 31, 2025. The company has until September 4, 2026, to submit a compliance plan and may ge...
